FDA Approved: CARBIDOPA, LEVODOPA, AND ENTACAPONE — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA approved a supplemental NDA from Sandoz Inc to market a fixed-dose combination of carbidopa, levodopa, and entacapone for Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Carbidopa, Levodopa and Entacapone (carbidopa/levodopa/entacapone)

Snippet

SUPPL AP for CARBIDOPA, LEVODOPA, AND ENTACAPONE (CARBIDOPA, LEVODOPA, AND ENTACAPONE)